Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Omegaven (fish oil triglycerides) is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Infection and Sepsis Risk: FO-ILEs significantly reduced infection risk compared to SO-ILEs (OR = 0.43, 90% CrI: 0.29-0.63), MCT/SO-ILEs (OR = 0.59, 90% CrI: 0.43-0.82), and OO-ILEs (OR = 0.56, 90% CrI: 0.33-0.91). Additionally, FO-ILEs significantly reduced sepsis risk compared to SO-ILEs (OR = 0.22, 90% CrI: 0.08-0.59).
• Hospital Length of Stay: FO-ILEs significantly reduced hospital length of stay compared to SO-ILEs (MD = -2.31 days, 90% CrI: -3.14 to -1.59) and MCT/SO-ILEs (MD = -2.01 days, 90% CrI: -2.82 to -1.22).
• PNALD in Infants: Fish oil-containing LEs significantly reduced cholestasis incidence in infants with PNALD compared to S-LEs (RR = 0.54, 95% CI: 0.32-0.91; RD = -0.39, NNTB = 3, 95% CI: 2-9) and significantly increased weight gain (45 g/week, 95% CI: 15.0-75.0).
• No significant differences in other adverse effects, such as death, sepsis, alkaline phosphatase, and alanine aminotransferase (ALT) levels, were reported between fish oil LEs and S-LEs. Mixed results were observed regarding hypertriglyceridaemia.
• There is no population types or subgroups information available in the reviewed studies.